ICON says it plans to acquire rival PRA Health Sciences in a $12 billion deal that would create one of the world’s largest CROs with the potential for a huge expansion into decentralized and hybrid clinical trials.

The merger would create the world’s second-largest CRO, after IQVIA. ICON currently ranks as the sixth-largest CRO in terms of revenue while PRA is the fifth-largest.